MOLECULIN BIOTECH INC (MBRX) Stock Price, Quote, News and Overview
NASDAQ:MBRX - Nasdaq - US60855D3098 - Common Stock - Currency: USD
MBRX Quote, Performance and Key Statistics
1.05
+0.04 (+3.96%)
The current stock price of MBRX is 1.05 USD. In the past month the price increased by 43.62%. In the past year, price decreased by -77.94%.
MBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About MBRX
Company Profile
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Company Info
MOLECULIN BIOTECH INC
5300 Memorial Dr Ste 950
Houston TEXAS 77007 US
CEO: Walter V. Klemp
Employees: 17
Phone: 17133005160
MOLECULIN BIOTECH INC / MBRX FAQ
What is the stock price of MOLECULIN BIOTECH INC today?
The current stock price of MBRX is 1.05 USD. The price increased by 3.96% in the last trading session.
What is the ticker symbol for MOLECULIN BIOTECH INC stock?
The exchange symbol of MOLECULIN BIOTECH INC is MBRX and it is listed on the Nasdaq exchange.
On which exchange is MBRX stock listed?
MBRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MOLECULIN BIOTECH INC stock?
9 analysts have analysed MBRX and the average price target is 10.88 USD. This implies a price increase of 936.19% is expected in the next year compared to the current price of 1.05. Check the MOLECULIN BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MOLECULIN BIOTECH INC worth?
MOLECULIN BIOTECH INC (MBRX) has a market capitalization of 14.70M USD. This makes MBRX a Nano Cap stock.
How many employees does MOLECULIN BIOTECH INC have?
MOLECULIN BIOTECH INC (MBRX) currently has 17 employees.
What are the support and resistance levels for MOLECULIN BIOTECH INC (MBRX) stock?
MOLECULIN BIOTECH INC (MBRX) has a support level at 1.02 and a resistance level at 1.05. Check the full technical report for a detailed analysis of MBRX support and resistance levels.
Should I buy MOLECULIN BIOTECH INC (MBRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MBRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MBRX, evaluating the profitability, health, valuation and growth aspects
- MOLECULIN BIOTECH INC (MBRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MOLECULIN BIOTECH INC (MBRX) Sales and EPS estimates to see what analysts future expectations are.
- MOLECULIN BIOTECH INC (MBRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MOLECULIN BIOTECH INC (MBRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- MOLECULIN BIOTECH INC (MBRX) Stock Chart to make your own analysis
- MOLECULIN BIOTECH INC (MBRX) Latest news and press-releases to stay up to date.
Does MOLECULIN BIOTECH INC (MBRX) stock pay dividends?
MBRX does not pay a dividend.
When does MOLECULIN BIOTECH INC (MBRX) report earnings?
MOLECULIN BIOTECH INC (MBRX) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of MOLECULIN BIOTECH INC (MBRX)?
MOLECULIN BIOTECH INC (MBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.94).
What is the Short Interest ratio of MOLECULIN BIOTECH INC (MBRX) stock?
The outstanding short interest for MOLECULIN BIOTECH INC (MBRX) is 3.35% of its float. Check the ownership tab for more information on the MBRX short interest.
MBRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MBRX. When comparing the yearly performance of all stocks, MBRX is a bad performer in the overall market: 81.23% of all stocks are doing better.
MBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MBRX. While MBRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
MBRX Financial Highlights
Over the last trailing twelve months MBRX reported a non-GAAP Earnings per Share(EPS) of -6.94. The EPS increased by 53.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -128.58% | ||
| ROE | -363.99% | ||
| Debt/Equity | 0 |
MBRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to MBRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.